Pharmaceutical companies’ co-marketing generates either ‘Jackpots’ or ‘Bankruptcies’

There is nothing new about co-marketing and co-promotion among pharmaceutical companies to be succeeded in certain product anymore. However, these types of cooperation do not guarantee success. The following are noticeable cases. 

Astrazeneca Korea and BMS Korea cooperated in both development and marketing for the Peptidase-4 Inhibitor-type diabetes drug ‘Onglyza’, but the result did not end w...